Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021
September 09 2021 - 4:05PM
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology
company developing the next generation of cancer and infectious
disease immunotherapies, today announced that it will host a data
update webcast for investors and analysts during the European
Society of Medical Oncology (ESMO) Annual Meeting 2021, September
17, 2021 at 1:30 p.m. ET.
The event will highlight the GRANITE (individualized neoantigen
immunotherapy) Phase 1/2 data in advanced solid tumors which is
being presented during a mini- oral presentation at ESMO 2021, in
addition to data from the SLATE v1 shared neoantigen immunotherapy
program in KRAS mutant advanced solid tumors.
Presenters:
- Andrew Allen, M.D., Ph.D., Gritstone’s chief executive
officer, will provide a brief overview of the company, its
neoantigen directed approach to immunotherapy, and next steps for
the GRANITE and SLATE oncology programs
- Daniel Catenacci, M.D., assistant professor of
medicine, University of Chicago, will review the most
recent GRANITE data
- Thierry Andre, M.D., professor of medical oncology, St.
Antoine Hospital, Assistance Publique Hôpitaux de Paris,
will discuss the current treatment landscape and unmet medical need
in treating patients with microsatellite stable colorectal cancer
(MSS-CRC)
The presentation will be followed by a Q&A session.
To register for the webinar, please click here. The call and
accompanying slides will be webcast live on the “Events” page under
the “Investors & Media” section of the company’s website at
www.gritstone.com. A replay of the webcast will be accessible at
the same link approximately one day after its completion.
Daniel Catenacci, M.D., is an associate professor of medicine
and director of the gastrointestinal oncology program at the
University of Chicago. He serves as the assistant director of
Translational Research in the Comprehensive Cancer Center. In
addition to his clinical practice as an adult gastrointestinal
medical oncologist, Dr. Catenacci is an active basic and clinical
researcher, focusing on the treatment of gastroesophageal
(esophagus, gastroesophageal junction, and stomach) cancers. His
bench-to-bedside translational research has an overarching goal to
validate and improve personalized treatment, immunotherapy, and
precision medicine for gastroesophageal cancer and other GI
cancers. Additionally, Dr. Catenacci designs and executes novel
clinical trials to implement treatment strategies based on these
laboratory and clinical discoveries. Dr. Catenacci serves as an
associate editor for the Journal of American Medical Association
Network Open (JAMA Netw Open) and is on the editorial board of the
Journal of Clinical Oncology Precision Oncology (J Clin Oncol
PO).
Thierry André, M.D., is a professor of medical oncology at the
University Pierre et Marie Curie (UMPC), Paris VI, and head of the
Medical Oncology Department in St. Antoine Hospital, Assistance
Publique Hôpitaux de Paris. He is the founding member and general
secretary of the GERCOR (Multidisciplinary Oncology Research Group)
and leads the colorectal task force of GERCOR and also serves as a
member of the Adjuvant Colon Cancer Endpoints (ACCENT) group. Dr.
André’s main research interest is in gastrointestinal malignancies.
Dr. André is a member of several scientific organizations including
the American Society of Clinical Oncology (ASCO) and the European
Society for Medical Oncology (ESMO), and was chairman of the GI
Cancer Board for Research of the French National Institute
(INCA).
About Gritstone Gritstone bio, Inc. (Nasdaq:
GRTS), a clinical-stage biotechnology company, is developing the
next generation of immunotherapies against multiple cancer types
and infectious diseases. Gritstone develops its products by
leveraging two key pillars—first, a proprietary machine
learning-based platform, Gritstone EDGE™, which is designed to
predict antigens that are presented on the surface of cells, such
as tumor or virally-infected cells, that can be seen by the immune
system; and, second, the ability to develop and manufacture potent
immunotherapies utilizing these antigens to potentially drive the
patient’s immune system to specifically attack and destroy
disease-causing cells. The company’s lead oncology programs include
an individualized neoantigen-based immunotherapy, GRANITE, and an
“off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which
are being evaluated in clinical studies. Within its infectious
disease pipeline, Gritstone is advancing CORAL, a COVID-19 program
to develop a second-generation vaccine, with support from
departments within the National Institutes of Health (NIH), the
Bill & Melinda Gates Foundation, the Coalition for Epidemic
Preparedness Innovations (CEPI) and through a license agreement
with La Jolla Institute for Immunology. Additionally, the company
has a global collaboration for the development of a therapeutic HIV
vaccine with Gilead Sciences. For more information, please visit
gritstone.com.
Gritstone Forward-Looking StatementsThis press
release contains forward-looking statements, including, but not
limited to, statements related to the potential of Gritstone’s
therapeutic programs; the advancements in the company’s ongoing
clinical trials; the timing of data announcements related to
ongoing clinical trials and the initiation of future clinical
trials. Such forward-looking statements involve substantial risks
and uncertainties that could cause Gritstone’s research and
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the drug development process, including Gritstone’s programs’ early
stage of development, the process of designing and conducting
preclinical and clinical trials, the regulatory approval processes,
the timing of regulatory filings, the challenges associated with
manufacturing drug products, Gritstone’s ability to successfully
establish, protect and defend its intellectual property and other
matters that could affect the sufficiency of existing cash to fund
operations. Gritstone undertakes no obligation to update or revise
any forward-looking statements. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to the business of the company in general, see
Gritstone’s most recent Quarterly Report on Form 10-Q filed on
August 5, 2021 and any current and periodic reports filed with the
Securities and Exchange Commission.
ContactsInvestors:Celia EconomidesChief
Financial OfficerIR@gritstone.com
Media:Dan Budwick1AB(973)
271-6085dan@1abmedia.com
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Apr 2023 to Apr 2024